Drug targeting by neo-lipoproteins

Journal of Controlled Release

Volumn 41, Issue 1-2, 1996, Pages 85-90

  Van Berkel, Theo J C ^a   Van Dijk, Marc C M ^a   Bijsterbosch, Martin K ^a   Rensen, Patrick C N ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Emulsions; Hepatitis B; Neo high density lipoprotein; Recombinant chylomicrons; Targeting

Indexed keywords

ANTIVIRUS AGENT; APOLIPOPROTEIN E; APOLIPOPROTEIN E RECEPTOR; CHOLESTEROL; CHOLESTEROL OLEATE; CHYLOMICRON; DIOLEOYLIODODEOXYURIDINE; IDOXURIDINE; LIPID EMULSION; LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PRODRUG; RADIOISOTOPE; TRIOLEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG UPTAKE; HEPATITIS B; INTRAVENOUS DRUG ADMINISTRATION; LIVER PARENCHYMA; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT;

EID: 0030222173     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(96)01359-4     Document Type: Conference Paper

References (12)

1. [1] M.K. Bijsterbosch and Th.J.C. van Berkel, Lactosylated high density lipoprotein: a potential carrier for the site-specific delivery of drugs to parenchymal liver cells, Mol. Pharmacol. 41 (1991) 404-411.
2. [2] R.C. Pittman, C.K. Glass, D. Atkinson and D.M. Small, Synthetic high density lipoproteins: application to studies of the apoprotein specificity for selective uptake of cholesterol esters, J. Biol. Chem. 262 (1987) 2435-2442.
3. [3] T.G. Redgrave and R.C. Maranhao, Metabolism of protein-free lipid emulsion models of chylomicrons in rats, Biochim. Biophys. Acta 835 (1985) 104-112.
4. [4] M.K. Bijsterbosch, D. Schouten and Th.J.C. van Berkel, Synthesis of the dioleoyl derivative of iododeoxyuridine and its incorporation into reconstituted high density lipoprotein particles. Biochemistry 33 (1994) 14073-14080.
5. 2-macroglobulin-recognition site, Biochem. J. 279 (1991) 863-870.
6. [6] R.W. Mahley, Apolipoprotein E: cholesterol transport protein with expanding role in cell biology, Science 240 (1988) 622-630.
7. [7] Th.J.C. van Berkel, J.K. Kruijt, L.M. Scheek and P.H.E. Groot, Effect of apolipoproteins E and C-III on the interaction of chylomicrons with parenchymal and non-parenchymal cells from rat liver, Biochem. J. 216 (1983) 71-80.
8. [8] T. Vogel, K.H. Weisgraber, M.I. Zeevi, H. Ben-Artzi, A.Z. Levanon, S.C. Rall Jr., T.L. Innerarity, D.Y. Hui, J.M. Taylor, D. Kanner, Z. Yavin, B. Amit, H. Aviv, M. Gorecki and R.W. Mahley, Human apolipoprotein E expression in Escherichia coli: structural and functional identity of the bacterially produced protein with plasma apolipoprotein E, Proc. Natl. Acad. Sci. USA 82 (1985) 8696-8700.
9. [9] A.A. Sinkula and S.H. Yalkowsky, Rationale for design of biologically reversible drug derivatives: prodrugs, J. Pharm. Sci. 64 (1975) 181-210.
10. [10] M. Huettinger, H. Retzek, M. Eder and H. Goldenberg, Characteristics of chylomicron remnant uptake into rat liver, Clin. Biochem. 21 (1988) 87-92.
11. [11] Z. Chen, A. Keech, R. Collins, B. Slavin, J. Chen, T.C. Campbell and R. Peto, Prolonged infection with hepatitis B virus and association with low blood cholesterol concentration and liver cancer, Br. Med. J. 306 (1993) 890-894.
12. [12] P.C.N. Rensen, M.C.M. van Dijk, E.C. Havenaar, M.K. Bijsterbosch, J.K. Kruijt and Th.J.C. van Berkel, Selective uptake of antivirals by recombinant chylomicrons: a new therapeutic approach to hepatitis B, Nat. Med. 1 (1995) 221-225.